EliSpot is used to detect an infection of borrelia and its co-infections on a cellular level; it is trustworthy and we have now been using it for several years. The first generation of enzymatic EliSpots provides important information about the infection from the cellular immune system.
We have now developed this test even further:
The new EliSpot, LymeSpot revised, delivers detailed information about the activity of the infection and /or inflammation. This test can better differentiate whether we are dealing with an active (specific effector-cells) or a latent (specific memory-cells) infection. It will now be possible to evaluate whether it is a patient’s infection, inflammation or autoimmune processes that are prevailing. In comparison with the EliSpot, which is based on the production of interferon-γ, LymeSpot also determines the cytokine IL-2. For more information, click here.
A new study to this was published on Febuary 12th 2015 showing the benefits for the therapeutic approach to determinate the two cytokines Gamma-Interferon and Interleukin-2, by EliSpot Assay in patients with acute and chronic Q-fever. Q-fever is also a tick-borne disease. For the study, click here.